Given the declining reimbursement, the per-study cost is a serious consideration,” says Hani Kayyali, president and CEO of sleep diagnostics company CleveMed. “Electronic devices that are used many times are inherently less expensive on a per usage basis than those used once because the cost of the device is spread over many uses. One, quite literally, is the financial cost. There are other costs too, say other stakeholders. (This also means Ectosense had to invest in a team of mobile developers to keep the connections running smoothly.) For example, Ectosense removed on-device memory, meaning NightOwl requires a connection with a smartphone. “I believe that physicians sometimes underestimate how a convenient test that speaks the language of the patient (ie, through an accompanying app) helps drive better testing and even therapy outcomes,” says Ectosense CEO Ciaran McCourt.īut for disposable devices to become cost-effective, “some trade-offs have to be made,” McCourt concedes. Producing over 10,000 NightOwl devices in November alone, fully disposable HST has allowed Ectosense to achieve scale advantages almost immediately out of the gate. ![]() Itamar Medical released the WatchPAT ONE in June 2019, and Ectosense released the NightOwl in June 2020. Two companies in particular have been marketing fully disposable versions of HST devices. Whereas patients have had to return the diagnostic base unit, they can now simply discard the entire device after receiving almost-immediate results-but this newfound agility comes with some costs. ![]() By Lindsey NolenĪlthough home sleep testing (HST) has been available to patients for some time, a new category of fully disposable HST devices is now changing the landscape for providers and patients alike. ![]() WatchPAT ONE and NightOwl ease cross-contamination worries and offer almost-immediate sleep apnea testing results.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |